Nine Chapters Capital Management LLC bought a new position in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 27,400 shares of the biopharmaceutical company’s stock, valued at approximately $133,000. Nine Chapters Capital Management LLC owned approximately 0.11% of ProQR Therapeutics N.V. as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Artal Group S.A. grew its holdings in shares of ProQR Therapeutics N.V. by 25.0% during the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of ProQR Therapeutics N.V. during the second quarter worth about $2,028,000. Finally, Redmile Group LLC grew its holdings in shares of ProQR Therapeutics N.V. by 2.8% during the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after buying an additional 43,050 shares during the last quarter. Institutional investors and hedge funds own 35.92% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “27,400 Shares in ProQR Therapeutics N.V. (PRQR) Purchased by Nine Chapters Capital Management LLC” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/04/27400-shares-in-proqr-therapeutics-n-v-prqr-purchased-by-nine-chapters-capital-management-llc.html.
PRQR has been the topic of a number of research reports. Zacks Investment Research raised ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a report on Wednesday, August 30th. ValuEngine raised ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. Finally, JMP Securities raised their price target on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $19.38.
Shares of ProQR Therapeutics N.V. (PRQR) traded up $0.15 on Friday, reaching $3.95. The company’s stock had a trading volume of 56,558 shares, compared to its average volume of 106,153. The company has a debt-to-equity ratio of 0.17, a current ratio of 8.22 and a quick ratio of 8.22.
ProQR Therapeutics N.V. Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.
Want to see what other hedge funds are holding PRQR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProQR Therapeutics N.V. (NASDAQ:PRQR).
What are top analysts saying about ProQR Therapeutics N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ProQR Therapeutics N.V. and related companies.